ATE175445T1 - Verfahren zur gewinnung von rekombinantem hepatitis b virus (hep b) oberflächeantigen - Google Patents

Verfahren zur gewinnung von rekombinantem hepatitis b virus (hep b) oberflächeantigen

Info

Publication number
ATE175445T1
ATE175445T1 AT91202615T AT91202615T ATE175445T1 AT E175445 T1 ATE175445 T1 AT E175445T1 AT 91202615 T AT91202615 T AT 91202615T AT 91202615 T AT91202615 T AT 91202615T AT E175445 T1 ATE175445 T1 AT E175445T1
Authority
AT
Austria
Prior art keywords
surface antigen
hep
virus
recombinant hepatitis
hepatitis
Prior art date
Application number
AT91202615T
Other languages
English (en)
Inventor
Gonzalez Verena Lucila Muzio
Arias Eduardo Penton
Garcia Manuel Palou
Escobar Giuvel Fontirrochi
Galvez Marcelo Nazabal
Griego Marta De Jesus Gonzalez
Asuncion Esquina
Iznaga Alejandro Beldarrain
Gonzalez Guillermo Juli Padron
Albajes Victoria Ramirez
Pena Arnaldo Garcia
Cruz Carlos Enrique Ruiz
Lopez Gladys Mabel Izquierdo
Y Josefina Gertrudis
Martinez Luis Herrera
Cano Carlos Antonio Duarte
Suarez Lilia Luisa Perez
Suarez Jose San Rafael Garcia
La Riva De La Riva Gustavo De
Avila Ramon Alexis Santiago
Zorilla Filiberto Rosendo Ayon
Meireles Rolando Paez
Fierro Alberto Agraz
Betancourt Raul E Diaz
Maya Yair Quinones
Original Assignee
Cigb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cigb filed Critical Cigb
Application granted granted Critical
Publication of ATE175445T1 publication Critical patent/ATE175445T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT91202615T 1990-10-08 1991-10-07 Verfahren zur gewinnung von rekombinantem hepatitis b virus (hep b) oberflächeantigen ATE175445T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU90155A CU22290A1 (es) 1990-10-08 1990-10-08 Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal

Publications (1)

Publication Number Publication Date
ATE175445T1 true ATE175445T1 (de) 1999-01-15

Family

ID=5459466

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98202021T ATE324451T1 (de) 1990-10-08 1991-10-07 Verfahren zur herstellung von recombinantem hepatitis b oberflächenantigen mit erhöhter immunogen-kapazität und verwendung in einer impfstoffzubereitung
AT91202615T ATE175445T1 (de) 1990-10-08 1991-10-07 Verfahren zur gewinnung von rekombinantem hepatitis b virus (hep b) oberflächeantigen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT98202021T ATE324451T1 (de) 1990-10-08 1991-10-07 Verfahren zur herstellung von recombinantem hepatitis b oberflächenantigen mit erhöhter immunogen-kapazität und verwendung in einer impfstoffzubereitung

Country Status (9)

Country Link
EP (2) EP0864649B1 (de)
JP (2) JP3189212B2 (de)
AT (2) ATE324451T1 (de)
AU (1) AU649482B2 (de)
CU (1) CU22290A1 (de)
DE (2) DE69130724T2 (de)
DK (2) DK0864649T3 (de)
ES (2) ES2129025T3 (de)
GR (1) GR3029582T3 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501126A (ja) * 1994-06-09 1998-02-03 セントロ デ インヘニエリア ヘネティカ イビオテクノロヒア 組換え単鎖Ｆｖ抗体断片、及び組換えＢ型肝炎ウイルス表面抗原の免疫精製のためのその用途
KR960023066A (ko) * 1994-12-10 1996-07-18 성재갑 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법
CU22642A1 (es) * 1996-12-12 2000-12-22 Ct Ingenieria Genetica Biotech Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
EP1403274A1 (de) * 2002-09-30 2004-03-31 Meristem Therapeutics Verfahren zur Reinigung von rekombinanten Proteinen aus komplexen Medien sowie die auf diese Weise erhaltenen gereinigten Proteine
CU23405A1 (es) * 2003-10-20 2009-08-04 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas para uso terapéutico
JP4936272B2 (ja) * 2006-02-13 2012-05-23 独立行政法人科学技術振興機構 バイオナノカプセルの効率的な精製法
CU23740A1 (es) 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
WO2017167317A1 (es) 2016-03-31 2017-10-05 Centro De Ingenieria Genetica Y Biotecnologia Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b
KR102630293B1 (ko) * 2021-06-21 2024-01-29 선지호 박스 포장 테이프 절단용 칼날유닛과 이를 이용한 박스 포장 테이프 절단장치.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59101426A (ja) * 1982-11-29 1984-06-12 Green Cross Corp:The Ｂ型肝炎感染予防用ワクチンの製造方法
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
DE3882154T2 (de) * 1987-02-27 1993-12-02 Merck & Co Inc Verfahren zur Herstellung des pres 1/S2/S-Hepatitis-B-Antigens aus Hefe.
US5004688A (en) * 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
IL89991A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of hepatitis b pres2 protein in methylotrophic yeasts
KR900008591B1 (ko) * 1988-05-13 1990-11-26 동아제약 주식회사 항이디오형 항체를 용출제로 사용하는 면역친화성 크로마토그라프법에 의한 생리활성물질의 정제방법

Also Published As

Publication number Publication date
JP2001231582A (ja) 2001-08-28
ES2129025T3 (es) 1999-06-01
EP0864649A2 (de) 1998-09-16
EP0480525B1 (de) 1999-01-07
DE69133525T8 (de) 2007-03-08
JP3189212B2 (ja) 2001-07-16
DE69130724D1 (de) 1999-02-18
CU22290A1 (es) 1995-01-31
DK0864649T3 (da) 2006-08-28
ATE324451T1 (de) 2006-05-15
ES2264183T3 (es) 2006-12-16
EP0480525A3 (en) 1992-09-30
DK0480525T3 (da) 1999-08-30
JPH0576370A (ja) 1993-03-30
EP0864649A3 (de) 1998-11-11
DE69130724T2 (de) 1999-06-17
GR3029582T3 (en) 1999-06-30
EP0480525A2 (de) 1992-04-15
DE69133525T2 (de) 2006-11-23
DE69133525D1 (de) 2006-06-01
AU8557491A (en) 1992-04-30
AU649482B2 (en) 1994-05-26
EP0864649B1 (de) 2006-04-26
JP3242640B2 (ja) 2001-12-25

Similar Documents

Publication Publication Date Title
ATE391784T1 (de) Verfahren und reagenzien zur erzeugung einer cd8+t-zellen immunantwort gegen hepatitis b oder c
ATE175445T1 (de) Verfahren zur gewinnung von rekombinantem hepatitis b virus (hep b) oberflächeantigen
HK1003032A1 (en) Novel antigens and methods for their preparation
DE69433971D1 (de) Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
EP0484787A3 (en) Hcv-specific peptides, process for obtaining them and their use
IE873314L (en) T cell epitopes of the hepatitis b virus nucleocapsid¹protein
DE59209512D1 (de) Hcv peptidantigene und verfahren zur bestimmung von hcv
EP0401941A3 (de) Hepatitis B-Virus-Oberflächen-Antigen und seine Herstellung
KR920002629A (ko) B형 간염 코어 항원의 아미노산 잔기 서열
EP0250253A3 (de) T- und B-Zellepitopen des pre-S-Gebietes des Hepatitis-B-Oberflächenantigens
EP0198299A3 (de) Verfahren zur Herstellung von Hepatitis-B-Oberflächenantigen enthaltenden Partikeln in neuer Form, die hoch immunogen sind
ATE473997T1 (de) Zur bildung von partikeln fähiges hbv-precore- protein
DE68926274D1 (de) Rekombinante HBsAg Hybridpartikel, die morphologische Eigenschaften von HBsAg-Antigen haben und eine immunogene Sequenz enthalten, die neutralisierende Antikörper gegen HIV induziert oder die von diesen Antikörpern erkannt ist, Nukleotide Sequenzen, die diese Partikel codieren und sie enthaltende Impfstoffe
DE3779032D1 (de) Dns-sequenz, vektoren, rekombinante viren und verfahren zur verwendung rekombinanter vaccinia-viren, die sich in cho-zellen vermehren koennen.
DE69128547D1 (de) Verfahren zur Herstellung von kondensierten Alkoholen mit einem Alkoxidkatalysator
DE3863469D1 (de) Verfahren zur herstellung von textilverstaerkung und damit erhaltenes gewebe.
DE3787121D1 (de) Verfahren zur Herstellung und Verwendung von Katzenleukämievirus-Antigenen.
BE1000167A4 (fr) Antigene du virus de l'hepatite b et procede pour sa production.
PT85052A (de) Verfahren zur herstellung einer pasteurisierten immunglobulin- praparation
DK257887A (da) Fremgangsmaade til fremstilling af hbcag i gaer og plasmid til brug ved udoevelse af fremgangsmaaden
ATE137505T1 (de) Schützende antikörper erregende plasmodium falciparum antigene und deren verwendung in impfstoffen
EP0293201A3 (de) Methode zur Impfung gegen Hepatitis-B-Virus
DE3750330T2 (de) Verfahren zur Herstellung eines Impfstoffs gegen Hepatitis B.
DK43991D0 (da) Allele varianter af plasmodium falciparum merozoitoverfladeantigen
JPS55136233A (en) Hb peptide vaccine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee